Menu
Menu
BRIUMVI (ublituximab-xiiy) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Briumvi is the anti-CD20 therapy that is administered as a twice yearly 1 hour infusion (after 2 initial loading doses)
Number of yearly treatments: 4
Potential side effects: Most common adverse reactions (greater than/equal to 10%) were infusion reactions such as pyrexia, chills, headache, flu-like illness, tachycardia, nausea, throat irriation, erythema and an anyphylactic reaction. Other common side effects were upper respiratory tract infections.
For a full list of potential side effects, please see the Briumvi website.
We offer expert infusion therapy without the hassle or cost of the hospital. We employ highly trained medical staff that work with health insurance companies & physicians to provide our patients with convenient care.
At Omega Health Clinics, we’re committed to offering affordable treatment, with upfront pricing and no hidden costs. Here’s how we make it happen.
